Copyright
©The Author(s) 2024.
World J Diabetes. May 15, 2024; 15(5): 886-897
Published online May 15, 2024. doi: 10.4239/wjd.v15.i5.886
Published online May 15, 2024. doi: 10.4239/wjd.v15.i5.886
Figure 1 Histological appearance of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis at 100 × magnification (hematoxylin and eosin stain).
A: A non-alcoholic fatty liver diseases activity score (NAS) 3/8; B: A NAS 6/8 which constitutes a moderate-severe steatohepatitis. Blue triangles denote macrovesicular steatosis. Black stars denote ballooned hepatocytes. Black bars in lower right corner denote scale bar of 50 μm.
- Citation: Gosnell JM, Golovko G, Arroyave E, Moghe A, Kueht ML, Saldarriaga OA, McKinney KH, Stevenson HL, Ferguson MR. Disparate outcomes in Hispanic patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis and type 2 diabetes: Large cohort study. World J Diabetes 2024; 15(5): 886-897
- URL: https://www.wjgnet.com/1948-9358/full/v15/i5/886.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i5.886